Symptom → Plant Sources
Coffee (Arabica & Robusta) (Coffea arabica) and Cognitive function: evidence and sources
inferred from neuroprotective action
For educational purposes only, not medical advice. Always consult a qualified practitioner before using medicinal plants, especially alongside prescribed medication, during pregnancy, or for a serious condition.
← Back to Symptom-to-Plant Lookup
Full Coffee (Arabica & Robusta) monograph →All plants for cognitive function →
Coffee is a complex mixture of chemicals that provides significant amounts of chlorogenic acid and caffeine. Unfiltered coffee is a significant source of cafestol and kahweol, which are diterpenes that have been implicated in the cholesterol-raising effects of coffee. The results of epidemiological research suggest that coffee consumption may help prevent several chronic diseases, including type 2 diabetes mellitus, Parkinson's disease and liver disease (cirrhosis and hepatocellular carcinoma). Most prospective cohort studies have not found coffee consumption to be associated with significantly increased cardiovascular disease risk. However, coffee consumption is associated with increases in several cardiovascular disease risk factors, including blood pressure and plasma homocysteine. At present, there is little evidence that coffee consumption increases the risk of cancer. For adults consuming moderate amounts of coffee (3-4 cups/d providing 300-400 mg/d of caffeine), there is little evidence of health risks and some evidence of health benefits. However, some groups, including people with hypertension, children, adolescents, and the elderly, may be more vulnerable to the adverse effects of caffeine. In addition, currently available evidence suggests that it may be prudent for pregnant women to limit coffee consumption to 3 cups/d providing no more than 300 mg/d of caffeine to exclude any increased probability of spontaneous abortion or impaired fetal growth.
Context The projected expansion in the next several decades of the elderly population at highest risk for Parkinson disease (PD) makes identification of factors that promote or prevent the disease an important goal. Objective To explore the association of coffee and dietary caffeine intake with risk of PD. Design, setting, and participants Data were analyzed from 30 years of follow-up of 8004 Japanese-American men (aged 45-68 years) enrolled in the prospective longitudinal Honolulu Heart Program between 1965 and 1968. Main outcome measure Incident PD, by amount of coffee intake (measured at study enrollment and 6-year follow-up) and by total dietary caffeine intake (measured at enrollment). Results During follow-up, 102 men were identified as having PD. Age-adjusted incidence of PD declined consistently with increased amounts of coffee intake, from 10.4 per 10,000 person-years in men who drank no coffee to 1.9 per 10,000 person-years in men who drank at least 28 oz/d (P Conclusions Our findings indicate that higher coffee and caffeine intake is associated with a significantly lower incidence of PD. This effect appears to be independent of smoking. The data suggest that the mechanism is related to caffeine intake and not to other nutrients contained in coffee. JAMA. 2000;283:2674-2679.
Position Statement: The position of The Society regarding caffeine supplementation and sport performance is summarized by the following seven points: 1.) Caffeine is effective for enhancing sport performance in trained athletes when consumed in low-to-moderate dosages (~3-6 mg/kg) and overall does not result in further enhancement in performance when consumed in higher dosages (>/= 9 mg/kg). 2.) Caffeine exerts a greater ergogenic effect when consumed in an anhydrous state as compared to coffee. 3.) It has been shown that caffeine can enhance vigilance during bouts of extended exhaustive exercise, as well as periods of sustained sleep deprivation. 4.) Caffeine is ergogenic for sustained maximal endurance exercise, and has been shown to be highly effective for time-trial performance. 5.) Caffeine supplementation is beneficial for high-intensity exercise, including team sports such as soccer and rugby, both of which are categorized by intermittent activity within a period of prolonged duration. 6.) The literature is equivocal when considering the effects of caffeine supplementation on strength-power performance, and additional research in this area is warranted. 7.) The scientific literature does not support caffeine-induced diuresis during exercise, or any harmful change in fluid balance that would negatively affect performance.
4 sources supporting Coffee (Arabica & Robusta) for Cognitive function. Includes scientific publications, books, monographs and traditional-use references.
Mechanistic basis
This use is associated with the plant's neuroprotective / cognition support action. Further evidence for that pharmacology:
Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by involuntary motor dysfunction and progressive cognitive impairment. This study aimed to explore the therapeutic potential of Coffea arabica (CA) phytoconstituents using a network pharmacology-based drug repurposing approach. CA-related Phytoconstituents were identified from public databases, while HD-related targets were retrieved from the DisGeNET database. Indoleamine 2,3-dioxygenase (IDO1) and huntingtin (HTT) were identified as two common overlapping targets using Venny 2.1. Protein-protein interaction (PPI) networks were constructed by CytoScape software. Gene ontology (GO) and KEGG pathway enrichment analysis, followed by MCODE and ClueGO software, revealed IDO1, HTT, PPAR-γ, ESR1, and CASP3 as key targets in HD pathogenesis. Among CA phytoconstituents, geraniol was selected based on its high binding affinity to IDO1 (PDB: 6V52), with a docking score of-8.01 kcal/mol compared to-4.39 kcal/mol for the reference inhibitor. Density functional theory (DFT) analysis showed a dipole moment of 2.50 Debye. Molecular dynamics simulations confirmed the stability of the IDO1-geraniol complex, with key interactions involving Ser167. In a 3-nitropropionic acid (3-NP)-induced HD animal model, geraniol (15 mg/kg) significantly improved motor function and cognitive performance, reduced lipid peroxidation and nitrite levels, and restored the activities of antioxidant enzymes (SOD, GSH, catalase). Neurotransmitter alterations (GABA, DA, glutamate, AChE) were also regulated. Histological studies revealed preservation of striatal neurons. These findings suggest that geraniol exerts neuroprotective effects in HD via modulation of IDO1 activity, oxidative stress, and neurotransmitter balance. SIGNIFICANCE STATEMENT: This study integrates network pharmacology, in silico modeling, and in vivo analysis to explore geraniol, a key metabolite of Coffea arabica, as a multi-target agent for Huntington's disease (HD). Geraniol showed strong binding to IDO1, restored cognitive and motor functions, balanced oxidative stress, and preserved striatal neurons in an HD rat model. Our findings suggest geraniol as a promising therapeutic candidate through modulation of IDO1, redox balance, and neurotransmitters.